ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES TEHREOF

Abstract

Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof.

1 .- 24 . (canceled) 
     
     
         25 . A method of treating an angiogenesis regulated disorder in a subject, comprising:
 a) identifying a subject in need of regulation of angiogenesis; and   b) administering to the subject an effective amount of an antibody or antigen-binging fragment thereof which binds HPTPbeta and regulates angiogenesis.   
     
     
         26 . The method according to  claim 25 , wherein angiogenesis regulated disorder is an angiogenesis elevated disorder selected from the group consisting of cancer, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget's disease, mycobacterial infections, Lyme's disease, systemic lupus erythematosis, Eales' discease, Behcet's disease, Best's disease, Stargardt's disease, pars planitis, hyperviscosity syndrome, toxoplasmosis, trauma and post-laser complications, and diseases associated with rubeosis. 
     
     
         27 . The method according to  claim 26 , wherein the antibody binds the N-terminal portion of HPTPβ. 
     
     
         28 . The method according to  claim 26 , wherein the antibody binds the first FN3 repeat of HPTPβ. 
     
     
         29 . The method according to  claim 28 , wherein the first FN3 repeat of HPTPβ has the sequence as shown in SEQ ID NO: 11, or a fragment thereof. 
     
     
         30 . The method according to  claim 26 , wherein the antibody is a monoclonal antibody. 
     
     
         31 . The method according to  claim 30 , wherein the monoclonal antibody is produced by hybridoma cell line ATCC No. PTA-7580 or a fragment of a monoclonal antibody according to  claim 30 , produced by hybridoma cell line ATCC No. PTA-7580. 
     
     
         32 . The method according to  claim 31 , wherein the antibody or an antigen binding fragment is humanized. 
     
     
         33 . The method according to  claim 26 , wherein the antibody binding fragment comprises heavy and light chain variable regions. 
     
     
         34 . The method according to  claim 33 , wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, and an F(ab′) 2  fragment. 
     
     
         35 . The method according to  claim 25 , wherein angiogenesis regulated disorder is an angiogenesis elevated disorder selected from the group consisting of inflammatory bowel diseases including Crohn's disease and ulcerative colitis, psoriasis, sarcoidosis, and rheumatoid arthritis. 
     
     
         36 . The method according to  claim 35 , wherein the antibody binds the N-terminal portion of HPTPβ. 
     
     
         37 . The method according to  claim 35 , wherein the antibody binds the first FN3 repeat of HPTPβ. 
     
     
         38 . The method according to  claim 37 , wherein the first FN3 repeat of HPTPβ has the sequence as shown in SEQ ID NO: 11, or a fragment thereof. 
     
     
         39 . The method according to  claim 35 , wherein the antibody is a monoclonal antibody. 
     
     
         40 . The method according to  claim 39 , wherein the monoclonal antibody is produced by hybridoma cell line ATCC No. PTA-7580 or a fragment of a monoclonal antibody according to  claim 30 , produced by hybridoma cell line ATCC No. PTA-7580. 
     
     
         41 . The method according to  claim 40 , wherein the antibody or an antigen binding fragment is humanized. 
     
     
         42 . The method according to  claim 35 , wherein the antibody binding fragment comprises heavy and light chain variable regions. 
     
     
         43 . The method according to  claim 40 , wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment, and an F(ab′) 2  fragment.